Lumify A Clear Bausch Consumer Sales Driver But COVID-19 Clouds Q1 Results And Guidance

Bausch reported global sales of Lumify eye drops, PreserVision supplements and other consumer health products up 8.9% to $353m. However, its net loss grew to $152m from $52m in the year-ago period on a $65m dent in its income due to mass postponements of ocular and dermatologic surgeries.

Q1 written on a speechbubble

Marketplace reaction to the COVID-19 pandemic drove nearly 9% sales growth for Bausch Health Companies Inc. consumer health products but also put a $65m dent in its income from slow Rx and medtech sales due to mass postponements of ocular and dermatologic surgeries.

The Canadian firm on 7 May reported first-quarter global sales of Lumify eye drops, PreserVision supplements and other consumer health...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from International

More from Geography